| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5770599 | ASTRAZENECA | Quinazoline derivatives |
May, 2017
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616582 | ASTRAZENECA | Quinazoline derivatives as anti-proliferative agents |
Jan, 2013
(11 years ago) | |
| US5457105 | ASTRAZENECA | Quinazoline derivatives useful for treatment of neoplastic disease |
Jan, 2013
(11 years ago) | |
| US5770599 | ASTRAZENECA | Quinazoline derivatives |
May, 2017
(7 years ago) | |
Iressa is owned by Astrazeneca.
Iressa contains Gefitinib.
Iressa has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Iressa are:
- US5616582
- US5457105
- US5770599
- US5770599
Iressa was authorised for market use on 05 May, 2003.
Iressa is available in tablet;oral dosage forms.
Iressa can be used as treatment of non-small cell lung cancer, first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations.
The generics of Iressa are possible to be released after 05 May, 2017.
Drugs and Companies using GEFITINIB ingredient
Market Authorisation Date: 05 May, 2003
Treatment: Treatment of non-small cell lung cancer; First-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions...
Dosage: TABLET;ORAL
IRESSA family patents
